In PDAC, activation of the oncogenic PI3K/AKT/mTOR signalling is linked to increased tumour growth, drug resistance and epithelial‐mesenchymal transition, weakened apoptosis and tumour immunogenicity, and worse pathological and clinical outcomes.44, 45, 46, 47, 48. This evidence concerns the gene MTOR and neoplasm.